

03 March 2016

'RESEARCH NEVER STOPS'

[info@evotec.com](mailto:info@evotec.com) | [www.evotec.com](http://www.evotec.com)

For further information,  
please contact

**Gabriele Hansen**  
*VP, Corporate Communications &  
Investor Relations*  
+49.(0)40.560 81-255  
+49.(0)40.560 81-333 Fax  
[gabriele.hansen@evotec.com](mailto:gabriele.hansen@evotec.com)

Evotec AG  
Manfred Eigen Campus  
Essener Bogen 7  
22419 Hamburg (Germany)

## Evotec to present at two upcoming IR conferences

**Hamburg, Germany – 03 March 2016:** Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The Netherlands, and at the 28<sup>th</sup> Annual Roth Conference in Dana Point, CA, USA.

### **BioCapital Europe 2016, Sofitel Legend Amsterdam The Grand in Amsterdam**

Date: Wednesday, 09 March 2016, 03.00 pm CET  
Venue: Sofitel Legend Amsterdam The Grand, Amsterdam,  
The Netherlands  
Presenter: Dr Werner Lanthaler,  
Chief Executive Officer of Evotec AG

### **28<sup>th</sup> Annual Roth Conference, The Ritz Carlton in Dana Point, CA**

Date: Tuesday, 15 March 2016, 01.00 pm PDT  
(9:00 pm CET)  
Venue: The Ritz Carlton, Dana Point, CA, USA  
Presenter: Dr Werner Lanthaler,  
Chief Executive Officer of Evotec AG

The PDF version and the direct link to the webcast of the presentation at 28<sup>th</sup> Annual Roth Conference will be provided at <http://www.evotec.com/>.

#### **ABOUT EVOTEC AG**

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to [www.evotec.com](http://www.evotec.com).

---

**FORWARD LOOKING STATEMENTS** — *Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*